These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 16445417)

  • 41. Etanercept: efficacy and safety.
    Jiménez-Puya R; Gómez-García F; Amorrich-Campos V; Moreno-Giménez JC
    J Eur Acad Dermatol Venereol; 2009 Apr; 23(4):402-5. PubMed ID: 19210697
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis.
    Strober B; Teller C; Yamauchi P; Miller JL; Hooper M; Yang YC; Dann F
    Br J Dermatol; 2008 Aug; 159(2):322-30. PubMed ID: 18503600
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Patient-reported outcomes in moderate-to-severe plaque psoriasis with scalp involvement: results from a randomized, double-blind, placebo-controlled study of etanercept.
    Tyring S; Bagel J; Lynde C; Klekotka P; Thompson EH; Gandra SR; Shi Y; Kricorian G
    J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):125-8. PubMed ID: 22188302
    [No Abstract]   [Full Text] [Related]  

  • 44. Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis.
    Elewski B; Leonardi C; Gottlieb AB; Strober BE; Simiens MA; Dunn M; Jahreis A
    Br J Dermatol; 2007 Jan; 156(1):138-42. PubMed ID: 17199580
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and safety of ustekinumab and etanercept for the treatment of psoriasis.
    Uhlenhake EE; Feldman SR
    Expert Opin Biol Ther; 2010 Jul; 10(7):1105-12. PubMed ID: 20446825
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Etanercept therapy for psoriasis in a patient with numerous comorbidities.
    De Simone C; Carbone A; Caldarola G
    Am J Clin Dermatol; 2010; 11 Suppl 1():49-50. PubMed ID: 20586510
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Etanercept in a 7-year-old boy with severe and recalcitrant psoriasis.
    Safa G; Loppin M; Bousser AM; Barbarot S
    J Am Acad Dermatol; 2007 Feb; 56(2 Suppl):S19-20. PubMed ID: 17097376
    [No Abstract]   [Full Text] [Related]  

  • 48. Safety and efficacy study on etanercept in patients with plaque psoriasis.
    Costanzo A; Mazzotta A; Papoutsaki M; Nisticò S; Chimenti S
    Br J Dermatol; 2005 Jan; 152(1):187-9. PubMed ID: 15656833
    [No Abstract]   [Full Text] [Related]  

  • 49. Successful treatment with etanercept of von Zumbusch pustular psoriasis in a patient with human immunodeficiency virus.
    Mikhail M; Weinberg JM; Smith BL
    Arch Dermatol; 2008 Apr; 144(4):453-6. PubMed ID: 18427038
    [No Abstract]   [Full Text] [Related]  

  • 50. Etanercept provides a more physiological approach in the treatment of psoriasis.
    Altomare G; Ayala F; Berardesca E; Chimenti S; Giannetti A; Girolomoni G; Lotti T; Martini P; Peserico A; Guerra AP; Vena GA
    Dermatol Ther; 2008 Oct; 21 Suppl 2():S1-14. PubMed ID: 18837727
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of etanercept on insulin secretion and insulin sensitivity in a randomized trial with psoriatic patients at risk for developing type 2 diabetes mellitus.
    Martínez-Abundis E; Reynoso-von Drateln C; Hernández-Salazar E; González-Ortiz M
    Arch Dermatol Res; 2007 Nov; 299(9):461-5. PubMed ID: 17726611
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cessation of cyclosporine therapy by treatment with etanercept in patients with severe psoriasis.
    Yamauchi PS; Lowe NJ
    J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S135-8. PubMed ID: 16488328
    [No Abstract]   [Full Text] [Related]  

  • 53. High-dose initiation of etanercept in psoriatic arthritis and plaque psoriasis: efficacy, safety and impact on patients' quality of life.
    De Felice C; Mazzotta A; Esposito M; Bianchi L; Chimenti S
    J Dermatolog Treat; 2006; 17(6):355-8. PubMed ID: 17853309
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Three significant cases of neutropenia with etanercept.
    Wenham C; Gadsby K; Deighton C
    Rheumatology (Oxford); 2008 Mar; 47(3):376-7. PubMed ID: 18180249
    [No Abstract]   [Full Text] [Related]  

  • 55. Infliximab in the treatment of psoriasis in patients previously treated with etanercept.
    Haitz KA; Kalb RE
    J Am Acad Dermatol; 2007 Jul; 57(1):120-5. PubMed ID: 17482715
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis.
    Lovell DJ; Reiff A; Jones OY; Schneider R; Nocton J; Stein LD; Gedalia A; Ilowite NT; Wallace CA; Whitmore JB; White B; Giannini EH;
    Arthritis Rheum; 2006 Jun; 54(6):1987-94. PubMed ID: 16732547
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Etanercept for the treatment of psoriasis and psoriatic arthritis.
    Gottlieb AB
    Dermatol Ther; 2004; 17(5):401-8. PubMed ID: 15379775
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Etanercept therapy allows the tapering of methotrexate and sustained clinical responses in patients with moderate to severe psoriasis.
    Yamauchi PS; Lowe NJ
    Int J Dermatol; 2008 Feb; 47(2):202-4. PubMed ID: 18211500
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Exacerbation of paranoid schizophrenia in a psoriatic patient after treatment with cyclosporine A, but not with etanercept.
    Di Nuzzo S; Zanni M; De Panfilis G
    J Drugs Dermatol; 2007 Oct; 6(10):1046-7. PubMed ID: 17966184
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of calcipotriol on etanercept partial responder psoriasis vulgaris and psoriatic arthritis patients.
    Campione E; Mazzotta A; Paternò EJ; Diluvio L; Prinz JC; Chimenti S
    Acta Derm Venereol; 2009; 89(3):288-91. PubMed ID: 19479128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.